A recent Nature Metabolism study reconstructs human MASLD progression as a continuous molecular trajectory rather than as a set of static histological stages. Within this trajectory-based framework, SREBF1 appears as a dynamic regulatory node. The authors place SREBF1 at the interface between lipogenic regulation, early stress responses and hepatocellular injury, citing Bitter et al. 2015 at this point. This context is notable for human SREBP1a biology. The 2015 study showed that human SREBP1a contributes significantly to hepatic lipogenic gene expression. In the new trajectory-based framework, this earlier human SREBP1a work is connected to a systems-level view of fatty liver disease progression, where metabolic regulation, cellular stress and disease-state transitions are analysed as part of a continuous molecular process. The relevance is therefore not the citation alone. It is the position of the citation. Human hepatic SREBP1a biology appears at the conceptual interface that is increasingly shaping the field: dynamic regulatory states, progression trajectories and stress-linked metabolic remodelling.

References

Kamzolas, I. et al. A data-driven framework reconstructs the molecular continuum of human MASLD progression. Nature Metabolism (2026). https://doi.org/10.1038/s42255-026-01543-7

Bitter, A. et al. Human sterol regulatory element-binding protein 1a contributes significantly to hepatic lipogenic gene expression. Cellular Physiology and Biochemistry 35, 803-815 (2015). https://doi.org/10.1159/000369739